With nearly 30 active clinical trials for advanced and/or rare cancers, TCRS is one of the leading centers for Phase I oncology trials in the nation. Clinical trials with agents directed at specific targets in patients' tumors were launched in November 2005. These clinical trials give options that did not exist before to Phoenix-area patients as well as patients from all over the country. TCRS is conducting clinical trials across a number of cancer types. Further development of cancer specific divisions in pancreatic cancer, breast cancer, leukemia, prostate cancer, lung cancer, and melanoma are under development.

In addition to clinical trials, a molecular profiling pilot study has been designed and implemented to test the hypothesis that treatment with a cancer agent selected based on the unique molecular profile of a patient's tumor may be more beneficial than a treatment selected based on the specific cancer type.

Patient participation in clinical trials is a necessary component to the research process. According to the National Institutes for Health, only 3% of adults with cancer are participating in clinical trials. At TCRS, the clinical trial participation rate is a remarkable 60%. Interestingly, a recent study shows that if given the opportunity and access to clinical trials, 63% of the population would participate, according to a survey by the Charlton Research Co.

Patient participation in clinical trials at TCRS includes:

- 125 visits per month

- 35-45 new patients per month

- 400-600 patient samples collected per month

For ALL patients inquiring about a particular study, please contact patient care coordinator, Joyce Schaffer.

Joyce Schaffer RN MSN OCN
Patient Care Coordinator
TGen Clinical Research Services @ SHC
Debi & Jerry Bisgrove Research Pavilion
10510 N. 92nd Street, Suite 200
Scottsdale, AZ 85258
Office 480-323-1339 or 1-877-273-3713
Fax 480-323-1276
Alternative Fax 480-323-1359
joschaffer@shc.org

Current Active Studies

1. A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas http://www.clinicaltrials.gov/ct2/show/NCT00844649?term=abi+gem+pancrease&rank=1
2. A Phase I Study of AR-12 in Adult Patients with Advanced or Recurrent Solid Tumors or Lymphoma, for Which No standard Therapy is Available http://www.clinicaltrials.gov/ct2/show/NCT00978523?term=ar-12&rank=1
3. A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients with Metastatic Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00825487?term=arq+621&rank=1
4. An Assessment of the Effect of Food and Antacid on BIIB021 Pharmacokinetics in Subjects With Advanced Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT01017198?term=biib021&rank=1
5. A Phase I, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynmaic Study of E6201 Administered Once Weekly for 3 Weeks (days 1, 8, and 15 of a 28-day Cycle) in Subjects with Advanced Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00794781?term=e6201&rank=2
6. A Phase I, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of EP-100 Given Intravenously 3 out of 4 weeks in Subject with Advanced Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00949559?term=ep-100&rank=1
7. An Open-Label, Phase I, Dose-Escalation Study of PI3 Kinase inhibitor (GDC-0941) in Patients with Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does not Exist or Has Proven Ineffective or Intolerable http://www.clinicaltrials.gov/ct2/show/NCT00876109?term=gdc0941&rank=3
8. A Phase I Open-label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genx-644282 in Patients with Advanced Malignant Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00942799?term=genz-644282&rank=1
9. A Phase I Study of IPI-504 and Docetaxel in Patients with Advanced Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00606814?term=infinity&recr=Open&rank=5
10. A Phase 1 Study of IPI-926 in patients with advanced and/or metastatic solid tumor malignancies http://www.clinicaltrials.gov/ct2/show/NCT00761696?term=ipi926&rank=1
11. A Phase I Dose-Escalation Study of LY2495655, an Anti-Myostatin Monoclonal Antibody, In Patients with Advanced Cancer
12. A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients with Pancreatic Cancer http://www.clinicaltrials.gov/ct2/show/NCT00839332?term=ly2603618&rank=1
13. A Dose Escalation Study Evaluating MK-1775 in Both Monotherapy and in combination with either Gemcitabine, Cisplatin or Carboplatin in Adult Patients with Advanced Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00648648?term=mk-1775&rank=1
14. A Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetic, Pharmacodynamics of Oral MP-470, A Multitargeted Tyrosine Kinase Inhibitor, in Patients with Solid Malignancies http://www.clinicaltrials.gov/ct2/show/NCT00504205?term=MP470&rank=1
15. A Phase I Dose Escalation Study of NKP-1339 in Patients with Advanced Solid Tumors Refractory to Treatment
16. A multicenter, Open Label, Randomized phase 2 Study to Evaluate the Efficacy and Safety of NKTR-102 (Peg Irinotecan) Versus Irinotecan in Patients with Second Line, Irinotecan Naïve, KRAS mutant, Colorectal Cancer http://www.clinicaltrials.gov/ct2/show/NCT00856375?term=nktr+102&rank=4
17. A Phase 2 Dose Escalation Study of NMS-1286937 Administered to Adult Patients with Advanced/Metastatic Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT01014429?term=nms-1286937&rank=1
18. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma http://www.clinicaltrials.gov/ct2/show/NCT00924989?term=osi906&rank=4
19. A Phase II Study of Coagulation Factor VIIA Inhibitor PCI-27483 In Pancreatic Cancer Patients
20. A Phase I Dose-Escalation Study of Bruton’s Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma http://www.clinicaltrials.gov/ct2/show/NCT00849654?term=pci-32765&rank=1
21. A Phase 1, Multicenter, Open-Label, Dose Escalation Trial of PDL192 in Subjects with Advanced Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00738764?term=pdl192&rank=1
22. A Phase I, multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients with Advanced Solid Tumor http://www.clinicaltrials.gov/ct2/show/NCT00834704?term=PEGPH20&rank=1
23. A Phase II Study of oral PHA-848125AC I patients with Thymic Carcinoma Previously treated with chemotherapy http://www.clinicaltrials.gov/ct2/show/NCT01011439?term=pha-848125ac&rank=1
24. A Phase I Study to Assess Safety, Pharmacakinetics, and Pharmacodynmaics of PLX3397 in Patients with Advanced, Incurable, Solid Tumor or Hematologic Malignancies in which the Target Kinases are linked to Disease Pathophysiology http://www.clinicaltrials.gov/ct2/show/NCT01004861?term=PLX3397&rank=1
25. A Phase I-Multi-Center, Open Label, Dose Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of PRLX93936 Administered Intravenously Daily for Five Days Followed by a 23 Day Rest Period in Patients With Advanced Solid Tumor http://www.clinicaltrials.gov/ct2/show/NCT00528047?term=PRLX+93936&rank=1
26. A Phase I Trial of Oral PX-478 (a HIF-1 Inhibitor) in Patients with Advanced Solid Tumors or Lymphoma http://www.clinicaltrials.gov/ct2/show/NCT00522652?term=PX-478&rank=1
27. A Multi-Center Phase 1, Dose-Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of RDEA119, a MEK Inhibitor, in Advanced Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00610194?term=rdea119&rank=2
28. A Phase 1 Study of SCH 900105 Administered by IV Infusion + Erlotinib in Advanced Solid Tumors or Lymphomas http://www.clinicaltrials.gov/ct2/show/NCT00725634?term=sch900105&rank=1
29. A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00907205?term=sf1126&rank=1
30. A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of SNX 5422 Mesylate in Subjects with Refractory Solid Tumor Malignancies http://www.clinicaltrials.gov/ct2/show/NCT00506805?term=SNX-5422&rank=1
31. A Phase 1 Dose Escalation Study of TAK 901 in Subjects with Advanced Hematologic Malignancies http://www.clinicaltrials.gov/ct2/show/NCT00807677?term=tak901&rank=1
32. A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients with Advances Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00495144?term=TH-302&rank=1
33. A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Solid Tumors or Lymphoma http://www.clinicaltrials.gov/ct2/show/NCT00688415?term=VTX-2337&rank=1
34. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00455052?term=XMT-1001&rank=1

12/09/2009